Compare Lululemon Athletica Inc (LULU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Repligen Corporation Common Stock — how do they compare? Lululemon Athletica Inc trades at $93.56 (market cap $10.44B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Lululemon Athletica Inc and Repligen Corporation Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 106 Days and Repligen Corporation Common Stock for 0 Days on average.
| LULU | RGEN | |
|---|---|---|
Market Cap | $10.44B | $11.14B |
Volume | 2,759,135 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $194.57 |
52-Week Low | $91.88 | $102.87 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $11.20B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.09, down 54% year-to-date and near its 52-week low. The technical picture is bearish with resistance at $96 and support at $93. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 12.78%, but faces growth concerns. Recent news highlights a securities fraud investigation and competitive pressures in athletic apparel.
The outlook is cautious due to legal overhangs and weakening sentiment, though valuation ratios like a P/E of 7.76 appear attractive. Risks include governance turmoil and consumer shifts. Analyst consensus is a $97.67 price target with a mixed buy/hold rating split, suggesting potential recovery if execution improves.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
